Baillie Gifford & Co. decreased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,358,581 shares of the company's stock after selling 131,067,285 shares during the period. Baillie Gifford & Co. owned about 6.04% of Ginkgo Bioworks worth $27,372,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Paloma Partners Management Co purchased a new stake in shares of Ginkgo Bioworks during the 1st quarter valued at about $28,000. Russell Investments Group Ltd. increased its holdings in Ginkgo Bioworks by 9,440.6% during the first quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company's stock valued at $37,000 after buying an additional 31,626 shares during the last quarter. Algert Global LLC bought a new position in Ginkgo Bioworks in the second quarter worth approximately $36,000. Wellington Wealth Strategies LLC. purchased a new position in shares of Ginkgo Bioworks during the 2nd quarter worth $41,000. Finally, Forbes J M & Co. LLP bought a new stake in shares of Ginkgo Bioworks during the 3rd quarter valued at $1,019,000. Hedge funds and other institutional investors own 78.63% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently commented on the company. TD Cowen raised their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, September 20th. BTIG Research raised their price objective on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research note on Friday, August 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $4.16.
View Our Latest Stock Report on Ginkgo Bioworks
Ginkgo Bioworks Stock Performance
DNA stock traded up $0.21 during trading on Wednesday, reaching $8.60. The company's stock had a trading volume of 3,455,423 shares, compared to its average volume of 1,134,952. The company has a fifty day moving average price of $7.70. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.26 and a 1 year high of $75.20.
About Ginkgo Bioworks
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Articles
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
